Nov 04, 2019
Medical Care Corporation Receives Funding to Validate Its Digital Biomarkers for Detecting Pre-Symptomatic Alzheimer's Disease
Nov 02, 2019
Green Valley Announces NMPA Approval Of Oligomannate For Mild To Moderate Alzheimer's Disease
Sep 13, 2019
Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease
Jul 12, 2019
Seqster Announces License of SRP(TM) to Boston University for Alzheimer's Disease Study at Alzheimer's Association International Conference® (AAIC) 2019
Jul 10, 2019
Alzheimer's Drug Discovery Foundation Clinical Trials Report Shows Notable Shift from Amyloid Approach
Nov 23, 2018
New Campaign by Alzheimer's Germ Quest Demands NIH Allocate $230 Million for Research on Alzheimer's Microbes
Oct 30, 2018
Advanced Clinical Enhances Alzheimer's Patient Recruitment and Retention with Cognitive Clinical Trials (CCT)
Oct 19, 2018
UsAgainstAlzheimer's Announces Projects to Advance the National Strategy for Recruitment and Participation in Alzheimer's Disease Clinical Research
Oct 09, 2018
AgeneBio Announces Two NIH Grant Awards to Advance its Therapeutic Pipeline to Combat Progression of Alzheimer's Disease
Sep 20, 2018
19th Annual Conference on Alzheimer's Drug Discovery Highlights Multiple Approaches to Prevent and Treat Alzheimer's Disease
Aug 07, 2018
BioArctic Obtains Exclusive Rights to Develop Antibody Treatments for Alzheimer's Disease from a Research Project Jointly Owned with Eisai
Aug 07, 2018
ProMIS Neurosciences Issues Narrated Commentary on Key Learnings from AAIC 2018
Aug 01, 2018
First Patient Enrolled In Biohaven's Phase 2/3 Mild-To-Moderate Alzheimer's Clinical Trial
Jul 21, 2018
Philanthropists Step Up With $109 Million For Alzheimer's Research
Jul 19, 2018
Innovative Alzheimer's Treatment from China Concludes Phase 3 Clinical Trials
Jul 17, 2018
New Coalition of Philanthropists Including Bill Gates and Leonard Lauder Commit More Than $30 Million to Develop New Tools to Diagnose Alzheimer's Disease
Jun 12, 2018
Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease
Nov 27, 2017
Second Phase 3 Study Results for LMTX® Published in the Journal of Alzheimer's Disease
Nov 01, 2017
New Report Highlights Innovation in Alzheimer's Clinical Trials
Sep 15, 2017
Biohaven And Alzheimer's Disease Cooperative Study (ADCS) Announce Phase 2 Clinical Trial Collaboration Evaluating Glutamate Modulating Agent Trigriluzole In Patients With Mild-To-Moderate Alzheimer's Disease